Evidence map›Paper›PMID 38437061›Full record

ArticleHepatology communications2024

Steroid responsiveness in alcohol-associated hepatitis is linked to glucocorticoid metabolism, mitochondrial repair, and heat shock proteins.

Josiah Hardesty, Meghan Hawthorne, Le Day, Jeffrey Warner, Dennis Warner, Marina Gritsenko, Aliya Asghar, Andrew Stolz, Timothy Morgan, Craig McClain and 2 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Josiah HardestyDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, Kentucky, USA.ORCID 0000-0003-1955-3046
Meghan HawthorneDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, Kentucky, USA.
Le DayDepartment of Biological Sciences, Biological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington, USA.
Jeffrey WarnerDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, Kentucky, USA.
Dennis WarnerDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, Kentucky, USA.
Marina GritsenkoDepartment of Biological Sciences, Biological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington, USA.
Aliya AsgharDepartment of Medicine and Research Services, Medicine and Research Services, VA Long Beach Healthcare System, Long Beach, California, USA.
Andrew StolzDepartment of Medicine, Division of Gastrointestinal and Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Timothy MorganDepartment of Medicine and Research Services, Medicine and Research Services, VA Long Beach Healthcare System, Long Beach, California, USA.
Craig McClainDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, Kentucky, USA.
Jon JacobsDepartment of Biological Sciences, Biological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington, USA.
Irina A KirpichDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky, USA.ORCID 0000-0002-9545-6451
University of Louisville · USPacific Northwest National Laboratory · USVA Long Beach Healthcare System · USUniversity of Southern California · US

Funding

The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANNA S. GUKOVSKAYA · 1999 to 2026
$45.8M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ZHANG, XIANG · 2016 to 2025
$24.1M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI SHIRISH S BARVE · 2016 to 2026
$17.9M
A prospective, randomized, clinical trial to evaluate two novel therapies, mycophU01AA021886 · NIAAA · SOUTHERN CALIFORNIA INST FOR RES/EDUC · PI MORGAN, TIMOTHY ROSS · 2013 to 2017
$3.1M
Integrated therapies for alcohol use and ALD (ITAALD) Network -UofL Clinical CenterU01AA026980 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN, Ashwani K Singal · 2018 to 2026
$2.9M
Role of Soluble Epoxide Hydrolase in Alcohol-Associated Liver DiseaseR01AA028905 · NIAAA · UNIVERSITY OF LOUISVILLE · PI Irina A. Kirpich · 2022 to 2026
$2.1M
The role of dietary unsaturated fat and inflammasome in alcoholic liver diseaseR01AA024102 · NIAAA · UNIVERSITY OF LOUISVILLE · PI KIRPICH, IRINA A. · 2016 to 2020
$1.7M
Mechanisms for alcohol induced gut barrier dysfunction in ALDR01AA023681 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2014 to 2018
$1.6M
Human Liver Tissue & Hepatocytes Research Resource (HLTHRR)R24DK139775 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DAVID A GELLER, Satdarshan Singh Monga · 2024 to 2026
$1.4M
Proteomic Investigations of Alcoholic HepatitisU01AA021918 · NIAAA · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI JACOBS, JON · 2013 to 2017
$1.3M
Restoration and preservation of hepatic cardiolipin levels promotes liver regeneration in AHR00AA030627 · NIAAA · UNIVERSITY OF LOUISVILLE · PI Josiah E Hardesty · 2024 to 2026
$732k
NCATS NIH HHS UL1 TR001414NIAAA NIH HHS F31 AA028423NIAAA NIH HHS F32 AA027950NIAAA NIH HHS K99 AA030627NIAAA NIH HHS L70 AA027913NIAAA NIH HHS P50 AA011999NIAAA NIH HHS P50 AA024337NIAAA NIH HHS R00 AA030627NIAAA NIH HHS R01 AA023681NIAAA NIH HHS R01 AA024102NIAAA NIH HHS R01 AA028905NIAAA NIH HHS R21 AA028117NIAAA NIH HHS U01 AA021886NIAAA NIH HHS U01 AA021918NIAAA NIH HHS U01 AA026934NIAAA NIH HHS U01 AA026980NIDDK NIH HHS R24 DK139775NIGMS NIH HHS P20 GM113226
6 · The paper itself

Abstract

backgroundAlcohol-associated hepatitis (AH) is one of the clinical presentations of alcohol-associated liver disease. AH has poor prognosis, and corticosteroids remain the mainstay of drug therapy. However, ~40% of patients do not respond to this treatment, and the mechanisms underlying the altered response to corticosteroids are not understood. The current study aimed to identify changes in hepatic protein expression associated with responsiveness to corticosteroids and prognosis in patients with AH.

methodsPatients with AH were enrolled based on the National Institute on Alcohol Abuse and Alcoholism inclusion criteria for acute AH and further confirmed by a diagnostic liver biopsy. Proteomic analysis was conducted on liver samples acquired from patients with AH grouped as nonresponders (AH-NR, n = 7) and responders (AH-R, n = 14) to corticosteroids, and nonalcohol-associated liver disease controls (n = 10). The definition of responders was based on the clinical prognostic model, the Lille Score, where a score < 0.45 classified patients as AH-R and a score > 0.45 as AH-NR. Primary outcomes used to assess steroid response were Lille Score (eg, improved liver function) and survival at 24 weeks.

resultsReduced levels of the glucocorticoid receptor and its transcriptional co-activator, glucocorticoid modulatory element-binding protein 2, were observed in the hepatic proteome of AH-NR versus AH-R. The corticosteroid metabolizing enzyme, 11-beta-hydroxysteroid dehydrogenase 1, was increased in AH-NR versus AH-R along with elevated mitochondrial DNA repair enzymes, while several proteins of the heat shock pathway were reduced. Analysis of differentially expressed proteins in AH-NR who survived 24 weeks relative to AH-NR nonsurvivors revealed several protein expression changes, including increased levels of acute phase proteins, elevated coagulation factors, and reduced mast cell markers.

conclusionsThis study identified hepatic proteomic changes that may predict responsiveness to corticosteroids and mortality in patients with AH.

Indexed as

Hepatitis, AlcoholicLiver Diseases, AlcoholicGlucocorticoidsHeat-Shock ProteinsHumansProteomicsSteroidsGlucocorticoidsHeat-Shock ProteinsSteroids

Identifiers

PMID38437061
PMCPMC10914234
OpenAlexW4392368448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.